Follow
Simone van den Elsen
Simone van den Elsen
University of Groningen, University Medical Center Groningen
Verified email at umcg.nl
Title
Cited by
Cited by
Year
Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs
MGG Sturkenboom, AG Märtson, EM Svensson, DJ Sloan, KE Dooley, ...
Clinical pharmacokinetics 60, 685-710, 2021
662021
Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring
SHJ van den Elsen, LM Oostenbrink, SK Heysell, D Hira, DJ Touw, ...
Therapeutic drug monitoring 40 (1), 17-37, 2018
512018
Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients
SHJ van den Elsen, MGG Sturkenboom, N Van't Boveneind-Vrubleuskaya, ...
Antimicrobial agents and chemotherapy 62 (12), e01092-18, 2018
422018
Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients
SHJ van den Elsen, MGG Sturkenboom, OW Akkerman, K Manika, ...
Antimicrobial Agents and Chemotherapy 63 (7), e00384-19, 2019
292019
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin
SHJ van den Elsen, OW Akkerman, EM Jongedijk, M Wessels, S Ghimire, ...
European Respiratory Journal 55 (5), 2020
222020
Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs
J Kuhlin, MGG Sturkenboom, S Ghimire, I Margineanu, ...
Clinical Mass Spectrometry 14, 34-45, 2019
222019
Membrane filtration is suitable for reliable elimination of Mycobacterium tuberculosis from saliva for therapeutic drug monitoring
SHJ van den Elsen, T van der Laan, OW Akkerman, AGM van der Zanden, ...
Journal of Clinical Microbiology 55 (11), 3292-3293, 2017
192017
Lack of penetration of amikacin into saliva of tuberculosis patients
SHJ van den Elsen, OW Akkerman, JR Huisman, DJ Touw, ...
European Respiratory Journal 51 (1), 1702024, 2018
172018
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
SHJ van den Elsen, OW Akkerman, M Wessels, EM Jongedijk, S Ghimire, ...
European Respiratory Journal 56 (4), 2020
142020
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a …
SHJ van den Elsen, MGG Sturkenboom, O Akkerman, L Barkane, ...
BMJ open 10 (6), e035350, 2020
62020
Cross-validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Quantification of Levofloxacin in Saliva
S Ghimire, EM Jongedijk, SHJ van den Elsen, MA Wessels, DJ Touw, ...
Journal of Applied Bioanalysis 6 (2), 68-70, 2020
52020
Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs”[Clin. Mass Spectrom. 14 (Part A)(2019) 34–45]
J Kuhlin, MGG Sturkenboom, S Ghimire, I Margineanu, ...
Journal of mass spectrometry and advances in the clinical lab 25, 72, 2022
12022
Therapeutic Drug Monitoring in Tuberculosis Treatment: the Use of Alternative Matrices and Sampling Strategies
S van den Elsen
Rijksuniversiteit Groningen, 2020
2020
Potentials for salivary therapeutic drug monitoring of anti-tuberculosis drugs
S van den Elsen
2018
The system can't perform the operation now. Try again later.
Articles 1–14